COMP <GO>
ENOV vs CDRE // EV/EBITDA & P/E VALUATION
Enovis Corporation (NYSE) VS. Cadre Holdings Inc. (NYSE) • 15-METRIC TALLY: ENOV 1
— CDRE 10
■ METRIC PARITY
LAST: $22.81 (+4.11%) • MKT CAP: $1.32B
valuation
—
LAST: $31.10 (+3.81%) • MKT CAP: $1.33B
valuation
20.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENOV VS. CDRE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENOV | CDRE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.80% | 42.50% | +17.30 | ENOV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | 11.00% | -43.70 | CDRE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 20.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.51% | 4.27% | -2.76 | CDRE | /fcf-yield <GO> |
| Operating Margin | -50.00% | 11.00% | -61.00 | CDRE | /operating-margins <GO> |
| Net Profit Margin | -52.70% | 7.20% | -59.90 | CDRE | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 7.50% | -0.80 | CDRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.16% | -1.16 | CDRE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.32 | -3.12 | CDRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | CDRE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 65.0 | -16.75 | CDRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 28.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.32B | $1.33B | -$16.3M | CDRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENOV REV | CDRE REV | ENOV GROSS % | CDRE GROSS % | ENOV FCF | CDRE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.25B | $610.3M | 59.8% | 42.5% | $19.9M | $56.8M |
| FY 2024 | $2.11B | $567.6M | 56.0% | 41.1% | -$67.2M | $26.1M |
| FY 2023 | $1.71B | $482.5M | — | — | $135.0M | $73.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENOV // BETA —
CDRE // BETA —